89bio starts phase 3 of pegozafermin for high triglycerides
gorodenkoff
- San Francisco-based 89bio (NASDAQ:ETNB) started a phase 3 trial of pegozafermin to treat patients with severe hypertriglyceridemia (SHTG).
- SHTG is a condition in which there is high level of a certain type of fat called triglycerides (TGs) in the blood. This raises the risk of heart and pancreas related diseases.
- The study dubbed, ENTRUST, is planned to enroll up to 360 patients who will receive either a 30 mg dose pegozafermin or 20 mg dose or a placebo. The main goal is the percent change from baseline in fasting triglycerides at week 26 compared to placebo.
- "We believe results from our previous trials in SHTG suggest a potentially favorable risk/benefit profile for pegozafermin as demonstrated through robust reductions in triglycerides, broad metabolic improvements including reductions in liver fat, as well as favorable safety and tolerability," said 89bio's Chief Medical Officer Hank Mansbach.
- The company's phase 2 trial called ENTRIGUE had met the main goal by showing statistically significant reductions in median TGs in patients across all dose groups treated with pegozafermin, compared to placebo.